Mitsubishi UFJ Asset Management Portfolio holdings
AUM
$125B
1-Year Return
23.89%
This Quarter Return
+4.3%
1 Year Return
+23.89%
3 Year Return
+93.04%
5 Year Return
+163.06%
10 Year Return
+400.91%
AUM
$82B
AUM Growth
+$9.65B
(+13%)
Cap. Flow
+$7.68B
Cap. Flow
% of AUM
9.36%
Top 10 Holdings %
Top 10 Hldgs %
31.42%
Holding
1,609
New
45
Increased
827
Reduced
158
Closed
37
Top Buys
| 1 |
Microsoft
MSFT
|
+$473M |
| 2 |
NVIDIA
NVDA
|
+$453M |
| 3 |
Apple
AAPL
|
+$433M |
| 4 |
Constellation Brands
STZ
|
+$379M |
| 5 |
Amazon
AMZN
|
+$281M |
Top Sells
| 1 |
Philip Morris
PM
|
+$343M |
| 2 |
Amphenol
APH
|
+$256M |
| 3 |
PXD
Pioneer Natural Resource Co.
PXD
|
+$74.4M |
| 4 |
Veralto
VLTO
|
+$69.5M |
| 5 |
iShares MBS ETF
MBB
|
+$34M |
Sector Composition
| 1 | Technology | 31.95% |
| 2 | Healthcare | 14.3% |
| 3 | Financials | 13.12% |
| 4 | Consumer Discretionary | 8.56% |
| 5 | Communication Services | 8.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
926
Stevanato
STVN
$7.15B
| $273K | ﹤0.01% |
14,905
+2,416
| +19% | +$44.3K |
|
927
Beam Therapeutics
BEAM
$2.12B
| $272K | ﹤0.01% |
11,610
+3,970
| +52% | +$93K |
|
|
ALX
928
Alexander's
ALX
$1.24B
| $271K | ﹤0.01% |
1,205
| – | – |
|
|
LAND
929
Gladstone Land Corp
LAND
$318M
| $266K | ﹤0.01% |
19,400
| – | – |
|
|
CLDT
930
Chatham Lodging
CLDT
$352M
| $265K | ﹤0.01% |
31,108
| – | – |
|
|
AUTL
931
Autolus Therapeutics
AUTL
$373M
| $259K | ﹤0.01% |
+74,398
| New | +$259K |
|
932
Fate Therapeutics
FATE
$120M
| $255K | ﹤0.01% |
+77,816
| New | +$255K |
|
|
VERV
933
DELISTED
Verve Therapeutics
VERV
| $254K | ﹤0.01% |
51,971
+32,958
| +173% | +$161K |
|
934
Intellia Therapeutics
NTLA
$1.24B
| $253K | ﹤0.01% |
11,287
+3,438
| +44% | +$76.9K |
|
935
BioNTech
BNTX
$24.5B
| $251K | ﹤0.01% |
3,127
+749
| +31% | +$60.2K |
|
936
Vir Biotechnology
VIR
$721M
| $251K | ﹤0.01% |
28,200
+4,221
| +18% | +$37.6K |
|
937
OmniAb
OABI
$232M
| $250K | ﹤0.01% |
66,648
+14,657
| +28% | +$55K |
|
938
Accuray
ARAY
$178M
| $247K | ﹤0.01% |
135,594
+82,004
| +153% | +$149K |
|
939
Novavax
NVAX
$1.33B
| $244K | ﹤0.01% |
19,311
-21,917
| -53% | -$277K |
|
940
Editas Medicine
EDIT
$245M
| $244K | ﹤0.01% |
52,254
+30,575
| +141% | +$143K |
|
941
Tango Therapeutics
TNGX
$717M
| $244K | ﹤0.01% |
+28,380
| New | +$244K |
|
942
Ocugen
OCGN
$328M
| $241K | ﹤0.01% |
+155,633
| New | +$241K |
|
943
4D Molecular Therapeutics
FDMT
$330M
| $240K | ﹤0.01% |
11,448
-7,519
| -40% | -$158K |
|
|
PKST
944
Peakstone Realty Trust
PKST
$486M
| $240K | ﹤0.01% |
22,620
| – | – |
|
945
Neurogene
NGNE
$273M
| $237K | ﹤0.01% |
+6,519
| New | +$237K |
|
946
Xencor
XNCR
$617M
| $236K | ﹤0.01% |
12,482
+298
| +2% | +$5.64K |
|
947
Arcturus Therapeutics
ARCT
$498M
| $235K | ﹤0.01% |
9,646
+7
| +0.1% | +$170 |
|
948
Immatics
IMTX
$718M
| $232K | ﹤0.01% |
+19,944
| New | +$232K |
|
949
Wave Life Sciences
WVE
$1.13B
| $227K | ﹤0.01% |
+45,557
| New | +$227K |
|
|
OLP
950
One Liberty Properties
OLP
$493M
| $226K | ﹤0.01% |
9,618
| – | – |
|